Arcus Biosciences (RCUS) Misses Q3 EPS by 5c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/24/2026

1. DECK
2. RNG
3. WDC
4. BYD
5. WCN
6. SPOT
7. BMY
8. SPY
9. FIX
10. TSCO

Go back to Arcus Biosciences (RCUS) Misses Q3 EPS by 5c

Arcus Biosciences Reports Third Quarter 2021 Financial Results and Provides an Update on our anti-TIGIT Domvanalimab

November 8, 2021 4:10 PM EST

Both domvanalimab-containing arms demonstrated differentiated clinical activity compared to that of zimberelimab alone in a second interim analysis of ARC-7, our randomized Phase 2 study in first-line metastatic non-small cell lung cancer (NSCLC) Gilead Sciences has initiated its opt-in review process for our anti-TIGIT program If the option is exercised and closed, Arcus would receive a $275 million opt-in payment, and the parties would share equally R&D expenses related to the anti-TIGIT program A decision is expected prior to the end of 2021 Updated... More